Advanced Practice Rheum: Rheumatoid & Inflammation Testing In this review, we'll be talking about labs, inflammation, and tests for rheumatoid arthritis. https://t.co/UlBuUhtB01 https://t.co/09OEk1OLs2

• Rheumatoid & Inflammation Testing | RheumNow

NEJM: Polymyalgia Rheumatica Drs. Dejaco and Matteson have published and update and review of polymyalgia rheumatica (PMR) in the NEJM. They lay out the initial approach to diagnosis, initial steroid dosing, management over time and when to use steroid sparing therapy. https://t.co/CGXjcY0J3H

Long-Term Bimekizumab Safety Data Adverse effects from bimekizumab through 2 years or more of treatment for psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA) were about as expected from shorter-term data, results from long-term extension studies indicated. https://t.co/hp2jVSGk8G

Real-world safety of tofacitinib vs biologics in 48,167 #PsA pts Rx w/ TOFA (3,166); TNFi (27K); IL-17Ai (20K); risankizumab (4,381); ustekinumab (4,499). Crude IRs/100 PY were 1.78-2.53 for serious infxn, 0.27–0.61 MI/stroke, 0.17–0.42 VTE, & 0.74–1.06 cancer. TOFA had signif https://t.co/dErlkyY9WC

Advanced Practice Rheum: Evaluation of Rheumatic Complaints In this review, Dr. Cush provides a systematic approach to evaluating musculoskeletal and rheumatic complaints in clinical practice. He emphasizes three key priorities: identifying "red flag" conditions (septic https://t.co/DwyO6FySxE

"At the end of the day, it’s not about what you have or even what you’ve accomplished. It’s about what you’ve done with those accomplishments. It’s about who you’ve lifted up, who you’ve made better. It’s about what you’ve given back." - Denzel Washington

EULAR 2025 Update for Behçet’s syndrome EULAR has updated its recommendations for the management of Behçet’s syndrome, the last being published in 2018. The current update carries no recommendations from the previous version: seven recommendations have content modifications, https://t.co/Xb6KyqsDXf

Economic analysis of ESR & CRP testing (are they same or different?). Compared to doing either ESR OR CRP, they found the ESR + CRP testing was cost-effective strategy, reducing misdiagnoses, followup costs and overall healthcare costs. https://t.co/UU15bxuPKP https://t.co/7aWwBM8CdY

• | CEOR | Dove Medical Press

Rush University MDHAQ surveys done on 1,337 pts (excluding primary FM), identified 30% w/ anxiety, 24% depression, 25% fibromyalgia, & 44% w any 3 of these. In this 44%, HIGHER pain (7 vs 4) and RAPID3 (17 vs 8.2) vs those without FM, anxiety, or depression (p< 0.001). https://t.co/xbOKeZj5cm

A retrospective cohort study of 195 renal Bx from 135 Lupus Nephritis pts, Mod-Severe interstitial fibrosis and tubular atrophy (IFTA) strongly assoc w/non-renal response & ESRD progression (HR 8.9) (also w/ age, SLE duration, prior LN flares, higher chronicity index) https://t.co/773xsk6IHZ

A multi-center, retrospective chart review of 82 Still's disease pts (63% female; mean Dx age 6.4 ± 4 yrs; F/U ~2.8 yrs). When analyzing Dz course, 34% were monophasic, 46% polyphasic (higher-than-expected), 19.5% persistent Dz. non-monophasic predicted by active 3 mos from Dx https://t.co/V7OxwEI4it

Autoantibodies Anonymous A new blog post from Dr. Artie Kavanaugh https://t.co/GodltmEexc https://t.co/Mv2zIvGHyv

• Autoantibodies Anonymous | RheumNow

Systemic Treatments for Chronic Plaque Psoriasis JAMA Dermatology has published a review of the pharmacologic landscape on managing adults with moderate to severe plaque psoriasis. https://t.co/fJQDvZDdbs https://t.co/IYAsdujsMf

• Systemic Treatments for Chronic Plaque Psoriasis | RheumNow

Spotty Medicare Coverage for Newer Rheumatoid Arthritis Meds Medicare coverage of targeted disease-modifying anti-rheumatic drugs (DMARDs) for RA -- both under Medicare Advantage and in separate Part D plans -- is likely to leave many patients wanting, researchers found. https://t.co/CW6gIHtnIw

Disease activity defined in adult-onset Still's dz. Criteria developed using Italian cohort 187 & 41 from CONSIDER (canakinumab) trial. Active AOSD based on 5 criteria: fever, plus 1: skin rash, arthritis, pt global>2 cm, CRP > 10 mg/L; or any 3 without fever (AUC 0.93, 0.85, https://t.co/J94pkQqZFP